{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02965904",
  "id": "02965904",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250704",
  "time": "0824",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250704/pdf/06lg88022kfm4w.pdf",
  "summary": "- **Milestone Achieved**: Completion of patient recruitment for the PANCOSIL trial (20 patients enrolled).  \n- **Key Trial Objective**: Assessing a novel CT-guided percutaneous delivery method for the OncoSil\u2122 device.  \n- **Catalyst**: Preliminary data expected in late 2025.  \n\nNo material trading or capital markets impact identified (no financial figures, timelines affecting capital structure, or liquidity events disclosed).",
  "usage": {
    "prompt_tokens": 1679,
    "completion_tokens": 86,
    "total_tokens": 1765,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-03T22:40:37.210636"
}